By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Halozyme Therapeutics, Inc. 

11388 Sorrento Valley Road

San Diego  California  92121  U.S.A.
Phone: 858-794-8889 Fax: 858-259-2539


SEARCH JOBS
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Key Statistics


Email: hr@halozyme.com
Ownership: Public

Web Site: Halozyme
Employees: 152
Symbol: HALO
 









Company News
Halozyme (HALO) To Host First Quarter 2016 Financial Results Conference Call 4/21/2016 6:36:18 AM
Halozyme (HALO) Expands Oncology Pipeline With Two Compounds Designed For Activity In The Tumor Microenvironment 4/19/2016 6:34:01 AM
Halozyme (HALO) To Present Data From Five Preclinical Studies At AACR Annual Conference 3/17/2016 9:08:50 AM
Halozyme (HALO) Doses First Patient In Phase 3 Clinical Trial Of PEGPH20 In Combination With ABRAXANE And Gemcitabine 3/16/2016 6:47:42 AM
Halozyme (HALO) Appoints Jim Daly To Board Of Directors 3/7/2016 7:30:58 AM
Halozyme (HALO) To Present At Upcoming Healthcare Conferences 3/3/2016 9:02:51 AM
Halozyme (HALO) Reports Fourth Quarter And Full Year 2015 Financial Results 3/1/2016 8:28:14 AM
Halozyme (HALO) To Host Fourth Quarter And 2015 Year-End Financial Results Conference Call 2/2/2016 7:00:10 AM
Halozyme (HALO) Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE Technology 1/21/2016 6:56:27 AM
Halozyme (HALO) Provides Key Program Updates, 2016 Financial Guidance At 34th Annual J.P. Morgan Healthcare Conference 1/11/2016 11:40:10 AM
12345678910...
//-->